MetLife Investment Management’s Adaptive Biotechnologies ADPT Stock Holding History

MetLife Investment Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.17M	Sell	84,082 -764	-0.9%	-$12.2K	0.01%	1329
2025 Q4	$1.38M	Sell	84,846 -4,405	-5%	-$71.9K	0.01%	1257
2025 Q3	$1.34M	Hold	89,251	–	–	0.01%	1295
2025 Q2	$1.04M	Buy	89,251 +21,290	+31%	+$193K	0.01%	1292
2025 Q1	$505K	Sell	67,961 -1,015	-1%	-$7.8K	﹤0.01%	1720
2024 Q4	$414K	Buy	68,976 +3,650	+6%	+$20.1K	﹤0.01%	1904
2024 Q3	$334K	Hold	65,326	–	–	﹤0.01%	1998
2024 Q2	$236K	Buy	65,326 +7,516	+13%	+$23.9K	﹤0.01%	2143
2024 Q1	$186K	Sell	57,810 -456	-0.8%	-$1.76K	﹤0.01%	2241
2023 Q4	$286K	Hold	58,266	–	–	﹤0.01%	2033
2023 Q3	$318K	Hold	58,266	–	–	﹤0.01%	1906
2023 Q2	$391K	Hold	58,266	–	–	﹤0.01%	1862
2023 Q1	$514K	Hold	58,266	–	–	﹤0.01%	1619
2022 Q4	$445K	Hold	58,266	–	–	﹤0.01%	1711
2022 Q3	$415K	Hold	58,266	–	–	﹤0.01%	1770
2022 Q2	$471K	Buy	58,266 +51,756	+795%	+$455K	﹤0.01%	1709
2022 Q1	$90.4K	Buy	+6,510	New	+$102K	﹤0.01%	2636

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MetLife Investment Management's ADPT Position: Q1 2026 in Review

MetLife Investment Management reduced its Adaptive Biotechnologies (ADPT) stake by 0.9% in Q1 2026, selling an estimated $12.2K and leaving 84,082 shares worth $1.17M. The position accounts for 0.01% of the portfolio, ranked #1329.

MetLife Investment Management first reported a position in ADPT in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.38M in Q4 2025. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

MetLife Investment Management held 84,082 shares of Adaptive Biotechnologies worth $1.17M as of Q1 2026.
MetLife Investment Management sold 764 Adaptive Biotechnologies shares in Q1 2026, an estimated $12.2K.
Adaptive Biotechnologies made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1329 holding.
MetLife Investment Management first reported a position in Adaptive Biotechnologies in Q1 2022 and has held it in 17 quarters since.
MetLife Investment Management's Adaptive Biotechnologies position peaked at $1.38M in Q4 2025.
295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.